INCYTE CORPORATION

Lobbying for INCYTE CORPORATION

Filing 2nd Quarter - Report

Reporting period

2nd Quarter 2026

Apr 1 - June 30 · Posted Jul 20, 2026

Expenses

$750,000.00

What this organization spent lobbying with its own staff. Reported using A: the three LDA methods count different costs, so an expenses figure is not comparable across filers that used different ones.

Client based in

Delaware

Official filing document

Government bodies contacted 4

Centers For Medicare and Medicaid Services (CMS)
Health & Human Services, Dept of (HHS)
HOUSE OF REPRESENTATIVES
SENATE

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when.

Bills named in this filing 4

HR 946
ORPHAN Cures Act
S 1862
ORPHAN Cures Act
HRES 1331
Expressing support for the designation of June 1, 2026, through June 7, 2026, as "Hidradenitis Suppurativa Awareness We…
S 2658
Medication Affordability and Patent Integrity Act

Lobbying activity 1

Medicare/Medicaid

H.R. 946 / S. 1862, Orphan Cures Act implementation H. Res. 1331, Expressing support for "Hidradenitis Suppurativa Awareness Week" S. 2658, Medication Affordability and Patent Integrity Act Issues related to Medicaid rebates Issues related to implementation of the Inflation Reduction Act Issues related to the 340B Drug Pricing Program Issues related to drug cost and pricing Education around access to innovative therapies in dermatology

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.